Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Next Previous
X
Search
Trial Profile

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Miransertib (Primary)
  • Indications Growth disorders; Proteus syndrome
  • Focus Expanded access; Therapeutic Use
  • Sponsors ArQule

    • Most Recent Events

    • 31 Jul 2021 Status changed from recruiting to completed.
    • 19 Oct 2018 According to an ArQule media release, preliminary data from two patients treated as part of this trial was presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting.
    • 27 Oct 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top